PDL BioPharma, Inc. (NASDAQ:PDLI) closed its last session at $3.08 with the change of +4.41%. The market capitalization of the company is $509.86M with an average Volume of 1.43 million shares. The stock currently has its 52-Week High range of $5.54 and 52-week low range of $2.58. The Price to Book (P/B) ratio stands at 0.66. The stock traded total quantity of 760.52 thousand shares.
Currently PDL BioPharma, Inc. (PDLI) captured an average recommendation of “ Hold ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “0″ Analysts”. “0” rated “Sell” for the company. “2” said the company as a “Hold”. Overweight rating was given by “0” and Underweight rating was given by “0”.
Analysts are expecting that the company to achieve $3.75 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $4.00 however minimum price target advised by analysts is $3.50. The Median price target for the stock is measured at $3.75.
Presently, Analysts decided consensus EPS estimate of $0.08 for present quarter and one month ago projected EPS estimate was at $0.08. If we take a look at back 3 month ago, consensus EPS estimate was $0.03.
A current consensus EPS estimate for next quarter is at $0.06 and 3 month ago EPS forecast was $0.04. Have a look at back 1 month ago, consensus EPS forecast was seen at $0.06.
For current fiscal year, most recent EPS estimate is set at $0.51 based on Analyst consensus and three month ago consensus EPS opinions was at $0.45. During period one month ago, consensus EPS forecast was decided at $0.51.
A current consensus EPS projection for next fiscal year is observed at $0.21 and one month ago consensus EPS forecast was at $0.21. Take a look at back three month ago, consensus EPS estimate opinions was decided at $0.06 by analysts.
One Month ago, the stock has gained consensus mean rating of Hold based on the analysis of brokerage analyst firms polled. 0 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 0. 2 advised the “Hold” rating about this stock. 0 revealed “Sell” signal and “Underweight” rating was declared by 0.
Three Months Ago, Analysts recommended an average brokerage rating of Hold derived from brokerage firms, according to FactSet. 0 said a “Buy Rating” and 0 announced “Overweight Rating”. 2 advised “Hold Rating” regarding the stock. 0 announced “Sell Rating” and 0 disclosed “Underweight Rating”.